Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026)
Krystal Biotech (KRYS) posted quarterly Return on Capital Employed of 14.97% for Q2 2026, up 128.0% year-over-year from 6.56% in Q2 2025, and up 5.3% on a QoQ basis from 14.21% in Q1 2026.
Krystal Biotech (KRYS) Return on Capital Employed (2017 - 2026) Analysis & Trends
Krystal Biotech has reported Return on Capital Employed for 10 years, with the latest figure at 14.97% in Q2 2026.
- Return on Capital Employed for Q2 2026 came in at 14.97%, up 128.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 14.97% (up 128.0% YoY), and the FY2025 annual result was 14.77%, up 690.0% from the prior year.
- Return on Capital Employed improved to 14.97% in Q2 2026, from 14.21% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 14.97% in Q2 2026 and troughed at 28.19% in Q1 2023.
- A 5-year average of 5.42% and a median of 5.56% in 2024 frame the typical range for Return on Capital Employed.
- The widest annual swing landed in 2022, when Return on Capital Employed slumped 1365 bps; it then soared 2401 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 26.96% in 2022, then soared by 47 bps to 14.21% in 2023, then surged by 150 bps to 7.17% in 2024, then soared by 90 bps to 13.62% in 2025, then increased by 10 bps to 14.97% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 14.97% in Q2 2026, 14.21% in Q1 2026, and 13.62% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 14.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.97% |
| Mar 31, 2026 | 14.21% |
| Dec 31, 2025 | 13.62% |
| Sep 30, 2025 | 14.42% |
| Jun 30, 2025 | 13.67% |
| Mar 31, 2025 | 11.02% |
| Dec 31, 2024 | 7.17% |
| Sep 30, 2024 | 3.21% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -8.56% |
| Dec 31, 2023 | -14.21% |
| Sep 30, 2023 | -20.81% |
| Jun 30, 2023 | -26.21% |
| Mar 31, 2023 | -28.19% |
| Dec 31, 2022 | -26.96% |
| Sep 30, 2022 | -23.59% |
| Jun 30, 2022 | -20.27% |
| Mar 31, 2022 | -18.56% |
| Dec 31, 2021 | -13.31% |
| Sep 30, 2021 | -13.81% |